Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients

Detalles Bibliográficos
Autores principales: Miot, Christelle, Parks, Deborah, Jerath, Maya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Mosby, Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895924/
http://dx.doi.org/10.1016/j.jaci.2022.12.614
_version_ 1784881952337166336
author Miot, Christelle
Parks, Deborah
Jerath, Maya
author_facet Miot, Christelle
Parks, Deborah
Jerath, Maya
author_sort Miot, Christelle
collection PubMed
description
format Online
Article
Text
id pubmed-9895924
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Mosby, Inc.
record_format MEDLINE/PubMed
spelling pubmed-98959242023-02-06 Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients Miot, Christelle Parks, Deborah Jerath, Maya J Allergy Clin Immunol Article Published by Mosby, Inc. 2023-02 2023-02-03 /pmc/articles/PMC9895924/ http://dx.doi.org/10.1016/j.jaci.2022.12.614 Text en Copyright © 2022 Published by Mosby, Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Miot, Christelle
Parks, Deborah
Jerath, Maya
Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
title Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
title_full Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
title_fullStr Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
title_full_unstemmed Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
title_short Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
title_sort tixagevimab and cilgavimab (evusheld – astrazeneca) efficacy in preventing covid infection in immunocompromised patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895924/
http://dx.doi.org/10.1016/j.jaci.2022.12.614
work_keys_str_mv AT miotchristelle tixagevimabandcilgavimabevusheldastrazenecaefficacyinpreventingcovidinfectioninimmunocompromisedpatients
AT parksdeborah tixagevimabandcilgavimabevusheldastrazenecaefficacyinpreventingcovidinfectioninimmunocompromisedpatients
AT jerathmaya tixagevimabandcilgavimabevusheldastrazenecaefficacyinpreventingcovidinfectioninimmunocompromisedpatients

Ejemplares similares